ClinicalTrials.gg
RecruitingNCT07360405Updated Oct 30, 2026

Dietary Intervention for Migraine Relief

An interventional study of Dietary training in Migraine, sponsored by American University. Recruiting at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by American University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.
Updated Oct 30, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 697 studies in Migraine Disorders with a site in United States — 92 open to participants now, 114 under way, 27 of them phase 3. Migraine Disorders · United States.

Planned enrollment
416th of 610
40 · median 78
Started
2026
with 35 others
No phase
204 of 697
31 open now
Primary completion
2026-12
later than 19 of 113 live
Registered
662nd of 697
by date

Among the 697 studies in Migraine Disorders with a site in United States, this one is the 416th largest by planned enrollment of the 610 interventional ones that give a count, is one of 36 that started in 2026, is one of 204 with no phase, reaches primary completion later than 19 of the 113 other live ones, and was the 662nd registered.

Migraine Disorders

1,660 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

92 of the 697 studies in Migraine Disorders with a site in United States are open now. Recruiting first, the newest first:

86 more — sign in →

All 92 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 697 studies in Migraine Disorders with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate whether a low-glutamate diet can improve migraine symptoms in adults with migraine and to explore possible biological changes associated with dietary improvement. The study focuses on whether reducing dietary glutamate intake may influence processes involved in migraine, such as brain excitation, inflammation, and oxidative stress.

The main questions this study aims to answer are:

Does following a low-glutamate diet reduce the number of migraine days and the severity and duration of migraine attacks, and improve quality of life?

Are improvements in migraine symptoms associated with changes in blood-based biological markers related to migraine activity?

Researchers will compare participants assigned to the low-glutamate diet with participants assigned to a wait-list control group to evaluate differences in migraine outcomes and related biological measures.

Participants will:

Complete a baseline run-in period while tracking headaches using a daily migraine diary

Either follow a low-glutamate dietary intervention or continue their usual diet as part of a wait-list control

Complete standardized questionnaires related to migraine symptoms and quality of life

Provide blood samples for laboratory analyses

Undergo neuroimaging assessments (for a subset of participants)

Read the detailed description

The purpose of this clinical trial is to evaluate whether a low-glutamate diet is an effective treatment for migraine and to explore how this dietary approach may influence biological processes related to migraine. The low-glutamate diet reduces intake of free glutamate commonly found in ultra-processed foods and food additives, while emphasizing whole foods rich in nutrients that support brain health and reduce oxidative stress.

The study is based on prior research showing that this diet led to substantial improvements in migraine symptoms among individuals with chronic pain, with migraine remission often observed after one month. These improvements were also associated with measurable changes in brain structure, suggesting a potential link between dietary glutamate exposure and migraine-related brain changes.

The primary goals of this study are to:

Determine whether one month on a low-glutamate diet reduces migraine frequency, severity, and duration and improves quality of life

Examine changes in blood markers related to migraine pain signaling

Assess whether dietary changes are associated with changes in brain structure or chemistry in a subset of participants

Participants will first complete a 4-week run-in period during which they will continue their usual diet and record headaches and migraines using a daily electronic diary. Eligible participants will then be randomly assigned to either begin the low-glutamate diet immediately or continue their usual diet for one additional month (wait-list control). All participants will complete questionnaires, provide blood and urine samples, and undergo in-person assessments at the end of each study phase. A subset of participants will also undergo Magnetic Resonance Imaging (MRI) scans.

Participants assigned to the diet will receive structured dietary training, educational materials, and weekly follow-up support to promote adherence. After the initial dietary phase, participants will complete a double-blind, placebo-controlled crossover challenge, during which they will receive short courses of monosodium glutamate (MSG) and placebo while remaining on the low-glutamate diet. This phase is designed to determine whether migraine symptoms return specifically in response to glutamate exposure.

Throughout the study, participants will continue to track migraine symptoms using daily diaries. The results of this study may help determine whether a low-glutamate diet is a safe, non-pharmacologic treatment option for migraine and may provide insight into dietary factors that contribute to migraine development and persistence.

03

Conditions studied

  • Migraine

Keywords

  • Migraine
  • Chronic pain
  • Diet
  • Glutamate
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women of all races and ethnicities
  • Age 18-75 years
  • Documented diagnosis of chronic or episodic migraine for at least 6 months, based on International Classification of Headache Disorders, 3rd edition (ICHD-III) criteria, defined as:

    • 8 headache days per month, and
    • 4 migraine days per month
  • Migraine onset before age 50
  • On a stable medication regimen for at least 1 month prior to enrollment
  • Willing to maintain stable medications throughout the study
  • Willing to discontinue supplements during the study period
  • Women of must be willing to use during the study timeframe

Exclusion criteria

Exclusion Criteria:

  • Current pregnancy, plans to become pregnant during the study timeframe, or current breastfeeding
  • Current use of medications affecting glutamatergic or gamma-Aminobutyric Acid (GABA) neurotransmission (unless discontinued under physician guidance)
  • Current use of quarterly injectable migraine preventive medications
  • Unwillingness to modify dietary intake or to stop alcohol and marijuana use during the study
  • Substance use disorder within the past year
  • Diagnosed seizure disorder
  • Severe asthma requiring past hospitalization
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Active comparator
    Diet group

    Behavioral: Dietary training

  • No intervention
    Control group

    This group will follow their own diet without any intervention. However after this period, they will given the chance of receiving intervention as well.

Interventions

  • BehavioralDietary training

    Subjects will undergo a 2-hour online training session to teach them how to follow the low glutamate diet. The low glutamate diet is a healthy, whole-food diet designed to limit the intake of free glutamate/aspartate, while also emphasizing the consumption of foods which are high in nutrients that protect against glutamate excitotoxicity and oxidative stress.

    Also known as: Low glutamate diet

06

What researchers measure

Primary outcomes

  1. Migraine days

    Changes in the number of migraine days with improvement defined as a ≥50% reduction in migraine days

    Time frame: 4 weeks

  2. Patient Global Impression of Change

    Changes in the patient Global Impression of Change score, where in this study improvement defined as the score of "much" or "very much" improved. This measure is a simple 1-to-7 scale where patients rate how much their condition or symptoms have improved. 1 means very much improved and 7 means very much worse.

    Time frame: 4 weeks

Secondary outcomes

  1. Migraine-specific quality of life

    Changes in the quality of life measured by the migraine-specific quality of life. This questionnaire scored 0-100 (higher is better).

    Time frame: 4 weeks

  2. Migraine duration

    Change in migraine duration (hours)

    Time frame: 4 weeks

  3. Migraine intensity

    Change in migraine intensity, measured in scale of 0 (least pain) to 10 (highest pain).

    Time frame: 4 weeks

  4. Skin carotenoid levels

    Change in the skin carotenoid levels (the score is measured by a biophotonic scanner)

    Time frame: 4 weeks

  5. Skin carotenoid levels

    Change in Skin carotenoid levels being measure using a biophotonic scanner

    Time frame: 4 weeks

  6. Glutathione

    Change in the blood levels of glutathione (micromol/L)

    Time frame: 4 weeks

  7. Coenzyme Q10

    Change in the serum level of coenzyme Q10 (mcg/mL)

    Time frame: 4 weeks

  8. 8-hydroxydeoxyguanosine (8OHdG)

    Change in the urine levels of 8-hydroxydeoxyguanosine (8OHdG) (mcg/g Creatinine)

    Time frame: 4 weeks

  9. Lipid peroxides

    Change in the urine level of lipid peroxides (micromol/g Creatinine)

    Time frame: 4 weeks

  10. Glutamate

    Change in the plasma levels of glutamate (micromol/dL)

    Time frame: 4 weeks

  11. Aspartate

    Change in the plasma levels of aspartate (micromol/dL)

    Time frame: 4 weeks

  12. Calcitonin gene-related peptide (CGRP)

    Change in the serum calcitonin gene-related peptide (CGRP) level

    Time frame: 4 weeks

  13. Brain levels of glutamate

    Measuring the change in the level of glutamate in brain using Magnetic resonance spectroscopy (MRS)

    Time frame: 4 weeks

  14. Brain level of glutathione

    Measuring the change in the level of glutathione in brain using Magnetic resonance spectroscopy (MRS)

    Time frame: 4 weeks

  15. Visual cortex thickness

    Changes in the visual cortex thickness measured via Magnetic Resonance Imaging (MRI)

    Time frame: 4 weeks

  16. Blood brain barrier permeability

    Change in blood brain barrier permeability will be assessed using magnetic resonance imaging (MRI) with 3-dimensional diffusion-prepared arterial spin labeling (3D DP-ASL), a non-invasive imaging technique for quantifying blood-brain barrier permeability.

    Time frame: 4 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Dec 2026, 9 months after the start.

Of 310 non-industry interventional studies with no phase under Migraine Disorders, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 36. This study's planned 9 months is below that.

Counting every sponsor, half of 360 studies reached it within 15 months; a quarter within 7 and three quarters within 33.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 30, 2026: start Jan 2026 → Mar 2026 and completion Mar 2027 → May 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2025
First posted
Jan 22, 2026
StartActual
Mar 2, 2026was Jan 2026
Primary completionEst.
Dec 2026
CompletionEst.
May 2027was Mar 2027
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 30, 2026
Sites
American University is now Recruiting
Oct 30, 2026
Start date
Jan 2026→Mar 2, 2026 (actual)
Oct 30, 2026
Study completion
Mar 2027→May 2027
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Not yet recruiting→Recruiting
    American University is now Recruiting
    Start date Jan 2026→Mar 2, 2026 (now actual)
    Study completion Mar 2027→May 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07360405
Lead sponsor
American University
Responsible party
Kathleen Holton (Professor, American University) — Principal investigator
First posted
Jan 22, 2026
Start date
Mar 2, 2026
Primary completion
Dec 2026 (estimated)
Completion
May 2027 (estimated)
Last update
Oct 30, 2026

Study contacts

Kathleen Holton
Contact
holton@american.edu
5037571578

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion